211 related articles for article (PubMed ID: 35799126)
1. HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects.
Fiore V; Rastrelli E; Madeddu G; Ranieri R; De Vito A; Giuliani R; Di Mizio G; Bolcato M; De Matteis G; Ialungo AM; Dell'Isola S; Starnini G; Babudieri S
BMC Infect Dis; 2022 Jul; 22(1):601. PubMed ID: 35799126
[TBL] [Abstract][Full Text] [Related]
2. HCV testing and treatment initiation in an Italian prison setting: A step-by-step model to micro-eliminate hepatitis C.
Fiore V; De Matteis G; Ranieri R; Saderi L; Pontali E; Muredda A; Ialungo AM; Caruso R; Madeddu G; Sotgiu G; Babudieri S
Int J Drug Policy; 2021 Apr; 90():103055. PubMed ID: 33310637
[TBL] [Abstract][Full Text] [Related]
3. Differences in HCV Seroprevalence, Clinical Features, and Treatment Outcomes between Female and Male Incarcerated Population: Results from a Matched Cohort Study.
Fiore V; De Vito A; Rastrelli E; Manca V; De Matteis G; Ranieri R; Pontali E; Geremia N; Panese S; Starnini G; Madeddu G; Babudieri S
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140655
[TBL] [Abstract][Full Text] [Related]
4. Incidence, prevalence and risk factors for hepatitis C in Danish prisons.
Søholm J; Holm DK; Mössner B; Madsen LW; Hansen JF; Weis N; Sauer AP; Awad T; Christensen PB
PLoS One; 2019; 14(7):e0220297. PubMed ID: 31348813
[TBL] [Abstract][Full Text] [Related]
5. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
[TBL] [Abstract][Full Text] [Related]
6. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
[TBL] [Abstract][Full Text] [Related]
7. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
[TBL] [Abstract][Full Text] [Related]
9. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran.
Hariri S; Alavi M; Roshandel G; Mohammadi Z; Fazel A; Amiriani T; Bazazan A; Motamed-Gorji N; Sohrabpour A; Merat S; Poustchi H; Malekzadeh R
Int J Drug Policy; 2021 Sep; 95():103269. PubMed ID: 33991887
[TBL] [Abstract][Full Text] [Related]
10. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
[TBL] [Abstract][Full Text] [Related]
11. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
[TBL] [Abstract][Full Text] [Related]
12. Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont.
Hale AJ; Mathur S; Dejace J; Lidofsky SD
Public Health Rep; 2023; 138(2):265-272. PubMed ID: 35264027
[TBL] [Abstract][Full Text] [Related]
13. The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017.
Crowley D; Lambert JS; Betts-Symonds G; Cullen W; Keevans M; Kelly E; Laird E; McHugh T; McKiernan S; Miggin SJ; Murphy C; Murtagh R; O'Reilly D; Tobin C; Van Hout MC
Euro Surveill; 2019 Apr; 24(14):. PubMed ID: 30968825
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of and risk factors for HBV and HCV among incarcerated people who inject drugs in Iran: A cross sectional study.
Moradi G; Mohamadi P; Zareie B; Rasouli MA; Gouya MM; Jafari S
BMC Infect Dis; 2020 Oct; 20(1):806. PubMed ID: 33129259
[TBL] [Abstract][Full Text] [Related]
15. Consensus recommendations on the management of hepatitis C in Australia's prisons.
Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
[TBL] [Abstract][Full Text] [Related]
16. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
17. Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.
Snow KJ; Young JT; Preen DB; Lennox NG; Kinner SA
BMC Public Health; 2014 Aug; 14():830. PubMed ID: 25113132
[TBL] [Abstract][Full Text] [Related]
18. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
[TBL] [Abstract][Full Text] [Related]
19. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
[TBL] [Abstract][Full Text] [Related]
20. HCV micro-elimination in two prisons in Milan, Italy: A model of care.
Giuliani R; Casigliani V; Fornili M; Sebastiani T; Freo E; Arzilli G; Scardina G; Baglietto L; Tavoschi L; Ranieri R
J Viral Hepat; 2020 Dec; 27(12):1444-1454. PubMed ID: 32815623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
